Bret Boudousquie

Stratus® Medical mission is to provide pain relief and improve the quality of life for chronic pain patients by Advancing RF Technology for the Treatment of Pain®. Stratus Medical has been recognized for innovation, revenue growth, & business performance by Deloitte Technology Fast 500, Pepperdine Most Fundable Companies, & The Houston Business Journal. Our unique and patented Nimbus RF Multitined Expandable Electrode was developed to address the unmet need for an easy to use, efficient, cost-effective radiofrequency ablation (RFA) device that provides a large volume and optimally shaped lesion, which interventional pain specialists can use to treat pain*. Nimbus provides predictable and sustained pain relief for patients suffering with chronic low back pain. Nimbus reduces procedural time and increases efficiency for hospitals and surgery centers where Nimbus is utilized. The Nimbus device is FDA cleared and CE marked. Nimbus has been utilized in ~300,000 patient treatments in the United States, Australia, Brazil, Canada, United Kingdom, Spain, and other countries. Copyright © Bret Boudousquie 2023 Nimbus®, Stratus® Medical & Advancing RF Technology for the Treatment Pain® are registered trademarks of Stratus Medical, LLC. *The Nimbus RF Multitined Expanandable Electrode is one treatment option for pain. Consult your physician for medical questions about your specific pain condition & treatment options. Nimbus RF results will vary. See IFU for full list of warnings and precautions.

Sailfish Investments develops commercial real estate for companies in the life science and medical technology industry.

Consulted on portfolio medical technologies including the NIMBUS RF assets, which ultimately I acquired with financial support from Wasatch to start Status Medical. Wasatch Health evaluates and invests in medical device technologies, products, and services that improve human health and wellness.

RadiaDyne®, an AngioDynamics (ANGO) company as of 9/21/2018, is a medical device and diagnostics company focused on patient monitoring of radiation dose for cancer patients during radiation treatments. OARtrac® is the first of its kind radiation dose monitoring platform which provides gold standard dose reading accuracy, real-time measurement, and proprietary intracavitary delivery devices. OARtrac provides dose information which helps facilitate adaptive radiotherapy with the goal to reduce side effects and provide better outcomes. RadiaDyne was built on US market leadership with the ImmobiLoc® Endorectal Balloon and Alatus® Vaginal Balloon, used to protect organs at risk during radiation therapy for prostate and cervical cancers. Position / Responsibilities / Results Led the transformation of RadiaDyne from a medical device company to a diagnostic and patient monitoring company resulting in sale to AngioDynamics. Established strategic plan approved by the board, developed team, established systems and processes for scale up and returned company to revenue growth. Executed pre-market clinical release of OARtrac and collaborated with R&D engineering team to bring to market OARtrac the first of its kind real-time, in vivo, radiation dose monitoring platform. Concurrent with OARtrac market release aligned the founder owners on five-year strategic plan to be funded by investor capital that would provide resources to scale sales team and support working capital needs. Led the capital raise process which resulted in several competitive funding options and ultimately sale and exceptional return for owners.

Advisory and consulting for medical device management teams for operations, finance, and M&A activities. MTA continues to operate but with limited activities since Stratus Medical was founded in December 2019.

SI-BONE (SIBN) created the minimally invasive sacroiliac fusion market for degenerative sacroiliac conditions with the novel and unique iFuse Implant System®. SI-BONE continues to lead this category with close to 100 peer reviewed clinical articles demonstrating safety and efficacy. The iFuse system has earned exclusive coverage by several national insurance companies and national healthcare systems across the world. Responsible for the market creation, start-up, market development, penetration, and acceptance of the novel iFuse sacroiliac fusion surgery in the South Texas market. Developed and executed professional education events, established referring physician network, conducted market development programs and delivered record setting surgeon evaluation and adoption of the iFuse sacroiliac joint fusion technology. Results and Accomplishments *Recognized for Sales Rep of the Year, Presidents Club (#1 /60), Quota Buster and Top Tier Sales Club at 2014 NSM. *Recognized for Presidents Club (#2 /60), Quota Buster and Top Tier Sales Club at 2013 NSM. *Recognized for Presidents Club (#2 / 50), Quota Buster, and Top Tier Sales Club at 2012 NSM. *Recognized in Q4 2011, Q1 2012, Q2 2012, Q3, 2012, Q4 2012, Q1 2013, Q2 2013, Q3 2013, Q2 2014, Q3 2014, & Q4 2014 for top revenue results and percent to quota. *Trained 40+ orthopedic spine surgeons and neurosurgeons on the iFuse technique with cadaver model and completed more than 35 first iFuse SI joint fusion surgeries during territory expansion from zero sales in 2011 to $2.5 million+ in sales revenue in 2014. *Selected for President’s Council in 2011, 2012, 2013, & 2014. *Field Trainer for 23 new sales and marketing representatives.

TranS1 (previously TSON) created the market category for the trans sacral approach to L5S1 to treat degenerative conditions of the lower lumbar spine. TranS1 was a pioneer in the shift to minimally invasive spine surgery developing and the minimally invasive AxiaLIF system, Vectre facet system and Avatar posterior fixation system. Positions & Responsibility Responsible for the market creation and early stage business development of the AxiaLIF MIS fusion technology. Established distributor and direct sales team, created and delivered sales training, invested in people & program development, developed marketing collateral & marketing programs, collaborated and developed professional education programs, established business plan and consistently exceeded sales plan. Results & Accomplishments *Region of the year in 2010 (#1 of 13 regions) leading Trans1 in total revenue, revenue growth and percent to quota. Six of seven Southwest direct sales representatives exceeded quota with three achieving Presidents Club. *Region of the Year 2009 (#1 of 8 regions) with four Southwest direct sales representatives selected for 2009 President’s Club. *Southwest Region grew from $1,000,000 in 2007 to $7,000,000 in 2010 with $2.5M or 90% growth in 2009 and $2.2M or 52% growth in 2010. *Responsible for national surgeon training program development and delivery in 2011 resulting in 75 new surgeons trained.

Ethicon Endo-Surgery, Inc., a subsidiary of Johnson & Johnson (JNJ), competing with USSC created the surgical stapling, advanced energy and minimally invasive general, thoracic, and GYN surgical markets. This space has grown from zero to over $10B globally since inception and reduced the trauma of surgery and cost of healthcare for millions of patients. Positions of Increasing Responsibility and Development Sales Representative, Virgina Senior Sales Representative, Virginia Sales Trainer, Virginia Sales Training Manager, Ohio Division Sales Manager, Texas & Louisiana Results & Accomplishments *Forecast Achievement 1999, 2000, 2001, 2002, 2004, 2005, 2006, 2007 *VP Forecast Achievement 2001, 2005 & 2006 *$500,000 Sales Club, $1,000,000 Sales Club, $1,500,000 Sales Club, $2,500,000 Sales Club & $5,000,000 Sales Club *Sales Excellence 2001

Wachovia (former NYSE ticker symbol WB) was a diversified commercial bank based in Charlotte, North Carolina. Before its acquisition by Wells Fargo in 2008, Wachovia was the fourth-largest bank holding company in the United States based on total assets. Positions Sales Consumer Banking Commercial Lending Analyst Commercial Loan Officer Commercial Loan Admistration, AVP Results & Accomplishments *Managed $500,000,000 commercial loan portfolio, Richmond, VA *Developed and managed $20,000,000 loan portfolio ($40,000,000 in commitments) Virginia Beach, VA